HEPARINISED SALINE INJECTION 50 IU/5ML
heparin sodium

PRODUCT INFORMATION

NAME OF THE DRUG
The active ingredient in Heparinised Saline injection is heparin sodium (porcine mucous).
The CAS number for heparin sodium is 9041-08-1.

DESCRIPTION
Heparin sodium is a preparation containing the sodium salt of a sulfated glucosaminoglycan present in mammalian tissues. On complete hydrolysis it liberates D-glucosamine, D-glucuronic acid, L-iduronic acid, acetic acid and sulfuric acid. It is prepared from the intestinal mucosa of pigs. Heparin sodium is a white or almost white powder, moderately hygroscopic, freely soluble in water.

Heparinised Saline Injection is a sterile solution of heparin sodium 10 IU/mL (50 IU/5 mL) with sodium chloride and water for injection adjusted to the correct pH with sodium hydroxide.

Heparinised Saline Injection contains no bacteriostatic agent and is intended for single use in a single patient only. Any solution remaining from an opened container should be discarded.

PHARMACOLOGY
Heparin is a naturally occurring mucopolysaccharide which inhibits the clotting of blood in vitro and in vivo. It enhances the rate at which antithrombin III neutralises thrombin and activated coagulation factors, e.g. factors IX, XI, XII and plasmin. Heparin itself has no effect on existing thrombi.

Pharmacokinetics
Heparin is not absorbed from the gastrointestinal tract. It is extensively bound to plasma proteins, does not cross the placenta and it is not distributed into breast milk. The half-life of heparin depends on the dose and route of administration as well as the method of calculation and is subject to wide inter- and intra-individual variation; a range of 1 to 6 hours with an average of 1.5 hours has been cited. It may be slightly prolonged in renal impairment, decreased in patients with pulmonary embolism, and either increased or decreased in patients with liver disorders. Heparin is taken up by the reticuloendothelial system. It is excreted in the urine, mainly as metabolites, although, after administration of large doses, up to 50% may be excreted unchanged.
INDICATIONS
Maintenance of the patency of intravenous injection devices.

CONTRAINDICATIONS
- Known hypersensitivity to heparin
- Use for anticoagulant therapy
- Severe thrombocytopenia
- Heparinised Saline Injection should not be administered to patients in an uncontrollable active bleeding state (see Precautions) except when this condition is the result of disseminated intravascular coagulation.

PRECAUTIONS
For patients with known coagulation problems, specialist advice should be sought before use.

Heparinised Saline Injection is not intended for intramuscular use.

Haemorrhage
Haemorrhage can occur at virtually any site in patients receiving heparin. An unexplained fall in haematocrit, a fall in blood pressure, or any other unexplained symptom warrants consideration of a haemorrhagic event. Heparinised Saline Injection should be used with caution in conditions in which there is an increased risk of haemorrhage, such as the following.

Gastrointestinal
Gastric or duodenal ulcers, continuous tube drainage of the stomach or small intestine.

Cardiovascular
Subacute bacterial endocarditis, severe hypertension.

Surgical
During and immediately after (a) spinal tap or spinal anaesthesia or (b) major surgery, especially that involving the brain, eye or spinal cord.

Haematological
Actual or potential haemorrhagic states, such as haemophilia, thrombocytopenia and some vascular purpuras.

Other
Menstruation, liver disease with impaired haemostasis.
**Thrombocytopenia**

Thrombocytopenia occurs in patients receiving heparin with a reported incidence of 0 to 30% and thrombocytopenia of any degree should be monitored closely. If the count falls below 100,000/mm$^3$ or if recurrent thrombosis develops (see White clot syndrome), Heparinised Saline Injection should be discontinued. If continued heparin therapy is essential, utilise heparin from a different organ source and reinstitute therapy with caution.

*Delayed Onset of HIT and HITT* Heparin-induced Thrombocytopenia (HIT) and Heparin-induced Thrombocytopenia and Thrombosis (HITT) can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.*

**White clot syndrome**

It has been reported that patients taking heparin may develop new thrombus formation in association with thrombocytopenia. This development is the result of the irreversible aggregation of platelets induced by heparin, i.e. the so-called white clot syndrome. The process may lead to severe thromboembolic complications such as skin necrosis, gangrene of the extremities that may lead to amputation, myocardial infarction, pulmonary embolism, stroke and possibly death. Therefore, Heparinised Saline Injection administration should be promptly discontinued if a patient develops new thrombosis in association with thrombocytopenia.

**Hypersensitivity**

As heparin is derived from animal tissues it should be used with caution in patients with a history of allergy as hypersensitivity reactions may occur.

**Incompatibilities**

Precautions must be exercised when drugs which are incompatible with heparin are administered through an indwelling intravenous catheter containing Heparinised Saline Injection (see Interactions with Other Drugs, Dosage and Administration).

**Use in Neonates/Infants**

Heparinised Saline Injection is not recommended for use in neonates. In infants, the cumulative amounts of heparin received from frequent administration of Heparinised Saline Injection during a 24 hour period should be considered.

**Use in Elderly Patients**

Elderly patients, particularly women, appear to have a higher risk of haemorrhage and should be carefully monitored.

**Carcinogenesis, Mutagenesis, Impairment of fertility**

No long-term studies in animals have been performed to evaluate the carcinogenic potential of heparin. Also, no reproduction studies in animals have been performed concerning mutagenesis or impairment of fertility.
Use in pregnancy  (Category C)
Animal reproduction studies have not been conducted with heparin sodium. It is also not known whether heparin sodium can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Heparinised Saline Injection should be given to a pregnant woman only if clearly needed.

Use in lactation
Heparin is not excreted in the breast milk.

Laboratory tests
Periodic platelet counts, haematocrits and tests for occult blood in the stool are recommended during the entire course of Heparinised Saline Injection use.

Interactions with other drugs
Platelet inhibitors
Drugs such as aspirin (acetylsalicylic acid), dextran, phenylbutazone, ibuprofen, indomethacin, dipyriramole, hydroxychloroquine, abciximab, eptifibatide, tirofiban and others that interfere with platelet aggregation reactions (the main haemostatic defense of heparinised patients) may induce bleeding and should be used with caution in patients receiving Heparinised Saline Injection.

Other interactions
Digitalis, tetracyclines, nicotine or antihistamines may partially counteract the anticoagulant action of Heparinised Saline Injection.

ADVERSE REACTIONS
Haematological
Haemorrhage is the major risk associated with heparin therapy although the low dose of Heparinised Saline Injection would not normally evoke this. An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug.

Hypersensitivity
Heparin may cause allergic reactions and possibly anaphylactic reactions. Generalised hypersensitivity reactions have been reported, with chills, fever and urticaria as the most common manifestations; asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions (including shock) have occurred more rarely. Itching and burning, especially on the plantar site of the feet, may occur.

Thrombocytopenia
Thrombocytopenia induced by heparin may be of two types. The first is an acute, but usually mild, fall in platelet count occurring within one to four days of initiation of therapy and which may resolve without cessation of treatment. A direct effect of heparin on platelet aggregation appears to be responsible. The second type is a
delayed onset thrombocytopenia, which has an immunological basis, and is more serious. It usually occurs after seven to eleven days of heparin and drug withdrawal is indicated. Thrombocytopenia of any degree should be monitored closely (see Precautions). Thrombocytopenia has been reported following small doses of heparin for catheter flushes.

**White clot syndrome**

White clot syndrome is a rare but serious complication to heparin therapy (see Precautions).

**Local irritation**

Skin necrosis at the injection site has been reported and is thought to be a local manifestation of heparin induced platelet aggregation and thrombosis. This should be taken as a warning sign in patients who develop it and heparin therapy should be immediately discontinued. Local irritation and erythema have also been reported.

**DOSAGE AND ADMINISTRATION**

Heparinised Saline Injection contains no antimicrobial agent. It is for single use in a single patient only. Discard any remaining contents.

To maintain the patency of intravenous injection devices and prevent clot formation, flush the catheter/ cannula with 10 to 50 IU every four hours. The solution may be used following initial placement of the device in the vein, after each injection of a medication, or after withdrawal of blood for laboratory tests. If the drug to be administered is incompatible with Heparinised Saline Injection (see Interactions with other drugs and Incompatibilities), the device must be flushed through with normal sodium chloride 0.9% solution before and after the drug is administered. When heparin would interfere with or alter the results of blood tests, the Heparinised Saline Injection solution should be cleared from the device by aspirating and discarding it before withdrawing the blood sample. Consult the device manufacturer's instructions for specific details.

Note. Since repeated injections of small doses of heparin can alter tests for activated partial thromboplastin time (APTT), a baseline value for APTT should be obtained prior to insertion of an intravenous device.

Usually Heparinised Saline Injection will maintain anticoagulation within the device for up to 4 hours.

**Incompatibilities**

Heparinised Saline Injection is incompatible with certain substances in solution. Specialised literature should be consulted to verify with which substances incompatibilities have been noted. The following incompatibilities have been reported: amikacin sulfate, erythromycin lactobionate, gentamicin sulfate, kanamycin sulfate, streptomycin sulfate, tetracycline sulfate, tobramycin sulfate, vancomycin hydrochloride, hydrocortisone sodium succinate, doxorubicin,
droperidol, ciprofloxacin, mitozantrone, morphine sulfate, haloperidol lactate, promethazine hydrochloride, codeine phosphate, hyaluronidase, penicillin G sodium, methadone hydrochloride, pethidine hydrochloride, reteplase, methicillin sodium, levorphanol bitartrate, alteplase, amiodarone hydrochloride, ampicillin sodium, aprotinin, cephalothin sodium, cytarabine, dacarbazine, daunorubicin hydrochloride, diazepam, dobutamine hydrochloride, netilmicin sulfate, oxytetracycline hydrochloride, polymyxin B sulfate, streptomycin sulfate, some phenothiazines and vinblastine sulfate.

OVERDOSAGE

Symptoms
The usual sign of overdosage is bleeding or haemorrhage. Nosebleeds, blood in urine or tarry stools may be noted as the first sign of bleeding. Easy bruising or petechial formations may precede frank bleeding.

Treatment
The drug should be withdrawn and clotting time and platelet count should be determined. Prolonged clotting time will indicate that there is an anticoagulant effect requiring neutralisation and in this case, protamine sulfate should be administered. The dose should be calculated by titration of the individual patient's requirements but as a general guide, approximately 1 mg of protamine sulfate neutralises 100 IU of heparin (mucous) that has been injected in the previous 15 minutes. No more than 50 mg should be administered, very slowly, in any ten minute period. Since heparin is being continuously eliminated the dose should be reduced as time elapses. Although the metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be assumed to have a half-life of about half an hour after intravenous injection.

Protamine may cause anaphylactoid reactions that may be life-threatening. (See the protamine product information for additional information.) Hence the drug should be given only when resuscitation techniques and treatment of anaphylactoid shock are readily available.

PRESENTATION

Polyamp Duofit® ampoules:
Heparinised Saline Injection 50 IU/5 mL in packs of 50

Storage
Store below 25°C

For single use in a single patient only. Discard any remaining contents.
POISON SCHEDULE OF THE DRUG

Prescription Only Medicine (S4)

NAME AND ADDRESS OF THE SPONSOR

AstraZeneca Pty Ltd
ABN 54 009 682 311
Alma Road
North Ryde NSW 2113
Australia

Date of TGA approval  19 November 2004
Date of most recent amendment  09 January 2007

*Please note changes to Product Information

POLYAMP DUOFIT is a trade mark of the AstraZeneca group of companies

© AstraZeneca Pty Ltd 2007